CRISPR, Five Ways – NPR
NPR |
CRISPR, Five Ways
NPR CRISPR, which stands for Clustered Regularly Interspaced Short Palindromic Repeats, is the basis for a revolutionary genome-editing technology that allows researchers to make very precise modifications to DNA. The implications are enormous — not only … |
NPR |
Five Different Ways To Explain CRISPR : 13.7: Cosmos And Culture …
NPR A new video offers a valuable introduction to CRISPR — and illustrates how understanding can evolve from a relatively short description to a dialogue with more … |
EurekAlert (press release) |
CRISPR tech leads to new screening tool for Parkinson’s disease
EurekAlert (press release) They are using CRISPR Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats) gene-editing technology. The system is one of research’s fastest growing biomedical techniques that allows scientists to make specific changes in the DNA of plants … |
|
A first: All respond to gene therapy in a blood cancer study
ABC News Doctors are reporting unprecedented success from a new kind of cell and gene therapy for multiple myeloma, a blood cancer that’s on the rise. Although it’s early and the study is small, 35 people, every patient responded to treatment and all but two … |
|
A first: All respond to gene therapy in a blood cancer study
ABC News Doctors are reporting unprecedented success from a new kind of cell and gene therapy for multiple myeloma, a blood cancer that’s on the rise. Although it’s early and the study is small, 35 people, every patient responded to treatment and all but two … |
|
HalioDx : HalioDx highlights use of Immunosign® to define CAR T-cell therapy signature in tumor at ASCO 2017
GlobeNewswire (press release) For the first time, a tumor microenvironment immune gene signature associated with CAR T-cell treatment of non-Hodgkin lymphoma (NHL) patients has been described. Data analysis pointed to immune programs which may facilitate or modulate anti-tumor … |
|
HalioDx : HalioDx highlights use of Immunosign® to define CAR T-cell therapy signature in tumor at ASCO 2017
GlobeNewswire (press release) For the first time, a tumor microenvironment immune gene signature associated with CAR T-cell treatment of non-Hodgkin lymphoma (NHL) patients has been described. Data analysis pointed to immune programs which may facilitate or modulate anti-tumor … |